RTI Surgical

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

RTI Surgical Inc. Receives FDA IDE Approval for the Clinical Investigation of Cortiva® Allograft Dermis in Breast Reconstruction

Retrieved on: 
Monday, November 27, 2023

ALACHUA, Fla., Nov. 27, 2023 /PRNewswire/ -- RTI Surgical, a leading global medical device organization, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for a clinical study designed to confirm the safety and effectiveness of Cortiva® Allograft Dermis in implant-based breast reconstruction.

Key Points: 
  • ALACHUA, Fla., Nov. 27, 2023 /PRNewswire/ -- RTI Surgical, a leading global medical device organization, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for a clinical study designed to confirm the safety and effectiveness of Cortiva® Allograft Dermis in implant-based breast reconstruction.
  • Olivier Visa, President and Chief Executive Officer of RTI Surgical, emphasized the company's commitment to advancing patient care by providing human acellular dermal matrix (ADM) for individuals undergoing breast reconstruction as part of their breast cancer treatment.
  • "This milestone marks a significant step towards obtaining FDA pre-market approval (PMA) for our Cortiva® allograft implants.
  • In consultation with the FDA, RTI Surgical developed a comprehensive clinical study to support its PMA application to obtain an indication for use in breast reconstruction.

Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical

Retrieved on: 
Monday, October 23, 2023

BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine.

Key Points: 
  • BELGRADE, Mont., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has acquired the nanOss production operations from RTI Surgical, Inc., a leading CDMO in regenerative medicine.
  • Under the terms of the purchase agreement, Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business, and assumed from RTI the lease for the nanOss production facility located in Greenville, NC.
  • Xtant previously acquired nanOss distribution rights and nanOss intellectual property with the acquisition of Surgalign’s assets related to its biologics and spinal fixation business in August 2023.
  • “This deal satisfies each element of our acquisition criteria and positions us to improve our manufacturing capabilities, capacity and cash flows.”

Bonalive Biomaterials Appoints Health Tech Executive Jort Kooistra

Retrieved on: 
Monday, October 2, 2023

Bonalive Biomaterials has appointed Jort Kooistra as vice president, Commercial Operations effective 2 October 2023.

Key Points: 
  • Bonalive Biomaterials has appointed Jort Kooistra as vice president, Commercial Operations effective 2 October 2023.
  • Jort Kooistra will bring his diverse background in business development, commercialization, and sales, combined with his strong foundation in medical training to Bonalive.
  • “We are excited to announce that such an experienced international health tech executive as Jort Kooistra is joining our team.
  • I look forward to contributing to this next phase of growth to bring Bonalive’s Smart Healing experience to an increasing number of surgeons and their patients worldwide”, Jort Kooistra, vice president, commercial operations, Bonalive Biomaterials.

Global Biosurgery Market Report to 2027 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022

The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosurgery - Global Market Insights, Competitive Landscape and, Market Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biosurgery market can be anticipated to grow at a CAGR of 9.23% during the forecast period of 2022-2027.
  • Key Takeaways from the Biosurgery Market Report Study:
    The effect of the COVID-19 pandemic on this market is significant.
  • To capture and analyze suitable indicators, our experts are closely watching the biosurgery market
    Key companies dominating the global biosurgery market.

Orthopaedic Industry Annual Report 2022: Leading Players, Product Segments, Revenue Figures and Forecasts, Growth drivers and Challenges - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The "The Orthopaedic Industry Annual Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Orthopaedic Industry Annual Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • Global orthopedic sales totaled $53.6 billion in 2021, an increase of 12.8% compared to 2020.
  • Published in late spring/early summer each year, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT is the definitive source for orthopedic market intelligence by reviewing key industry trends, highlighting strategic product launches and M&A activity, and offering a five-year forecast of the market.
  • We cover the leading players; product segments, revenue figures and forecasts, growth drivers and challenges.

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022

ATLANTA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the third quarter and nine months ended September 30, 2022 and provided a corporate update.

Key Points: 
  • units of FemVue sold increased by 38.9% for the three months ended September 30, 2022 compared to the same period last year.
  • International sales decreased by 33.4% and were $115,859 and $174,077 for the nine months ended September 30, 2022 and 2021, respectively.
  • Cost of sales increased by $50,407, or 16.5%, to $356,479 for the nine months ended September 30, 2022 compared to $306,072 for the nine months ended September 30, 2021.
  • Gross margin percentage was 63.3% for the nine months ended September 30, 2022 compared to 66.9% for the nine months ended September 30, 2021.

Orbion Space Technology Appoints Dan Webber as CFO

Retrieved on: 
Tuesday, November 1, 2022

HOUGHTON, Mich., Nov. 1, 2022 /PRNewswire/ -- Orbion Space Technology, Inc., a manufacturer of advanced propulsion systems for satellites, announced the appointment of Dan Webber to Chief Financial Officer.

Key Points: 
  • HOUGHTON, Mich., Nov. 1, 2022 /PRNewswire/ -- Orbion Space Technology, Inc., a manufacturer of advanced propulsion systems for satellites, announced the appointment of Dan Webber to Chief Financial Officer.
  • "Dan has decades of experience in areas that are crucial to Orbion's future," said Brad King, Co-founder and CEO of Orbion.
  • Prior to that Webber was CFO and then CEO of Pioneer Surgical Technology, a developer of orthopedic devices serving global medical implant end markets in Spine, Trauma, and Biologics.
  • Orbion Space Technology develops and manufactures revolutionary plasma propulsion systems for small satellites.

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

Retrieved on: 
Wednesday, October 12, 2022

Ms. Thomas will be leading all regulatory and clinical efforts for the FemBloc and FemaSeed clinical programs at Femasys.

Key Points: 
  • Ms. Thomas will be leading all regulatory and clinical efforts for the FemBloc and FemaSeed clinical programs at Femasys.
  • Prior to this, she was vice president of regulatory, clinical, and quality at RTI Surgical, a leading surgical implant supplier.
  • Previously, Ms. Thomas served as vice president of regulatory and clinical at Cardiac Science Corp. and vice president of regulatory, quality, compliance, regulatory and clinical, and regulatory and design assurance over her tenure at Smiths Medical.
  • She also served as vice president/head of regulatory at Vascular Solutions and regulatory manager in the emerging therapies division at AMS.